[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547449":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":40,"locations":47,"responsibleParty":71,"collaborators":29,"id":75,"slug":29,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":29,"enrollmentInfo":84,"targetDuration":29,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":29,"overallStatus":50,"whyStopped":29,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Hospital Heidelberg","OTHER",[8,13,18],{"label":9,"type":6,"description":10,"interventionNames":11},"Group 1, Surgery","cT1-2 N0, all histologies: primary surgical therapy",[12],"Procedure: surgical therapy",{"label":14,"type":6,"description":15,"interventionNames":16},"Group 2, Chemotherapy and surgery","cT3-4 and\u002For N+, adenocarcinomas: neoadjuvant chemotherapy, surgical therapy",[12,17],"Drug: Chemotherapy",{"label":19,"type":6,"description":20,"interventionNames":21},"Group 3, chemotherapy, radiotherapy and surgery","cT3-4 and\u002For N+, squamous cell carcinomas: neoadjuvant radio(chemo)therapy, surgical therapy",[22,12,17],"Radiation: photon",[24,30,35],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"RADIATION","photon","radiation with 4-5 cm safte margin",[19],null,{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":29},"PROCEDURE","surgical therapy","surgery based on PET-CT\u002FMRI staging",[9,14,19],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":29},"DRUG","Chemotherapy","neoadjuvant chemotherapy",[14,19],[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Christoph Fink, MD","CONTACT","+496221 56","8201","christoph.find.@med.uni-heidelberg.de",[48],{"facility":49,"status":50,"city":51,"state":29,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Department of Radiotherapy, University of Heidelberg","RECRUITING","Heidelberg","69120","Germany",{"type":55,"coordinates":56},"Point",[57,58],8.69079,49.40768,{"lat":58,"lon":57},[61,66],{"name":62,"role":43,"phone":63,"phoneExt":64,"email":65},"Juergen Debus, Prof. Dr. Dr.","+49 6221 56","8200","juergen.debus@med.uni-heidelberg.de",{"name":67,"role":43,"phone":68,"phoneExt":69,"email":70},"Adriane Lentz-Hommertgen, Dr. rer. nat.","0622156","34091","adriane.lentz-hommertgen@med.uni-heidelberg.de",{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Juergen Debus","Department head","100547449",false,"NCT06408116","Predicting Esophageal Cancer Borders Using PET-Imaging","Predicting Esophageal Cancer Borders Using PET-Imaging PEGASUS","PEGASUS","Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus, including AEG I and AEG II tumors in the primary situation\n* Planned surgical treatment of esophageal carcinoma\n* Possible staging advantage through FAPI PET\u002FCT diagnostics\n* Patient information and written consent\n\n  -\\> KI 60% or ECOG 0\u002F1 (at least: self-sufficiency)\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Previous radiation therapy in the tumor region\n* Previous tumor disease with \\\u003C 5 years of remission\n* Surgical therapy is not functionally or technically possible\n* Distant metastasis\n* Patient is not capable of giving consent\n* Concurrent participation in another clinical trial that could affect the results of this trial or the other trial\n* Illnesses that do not allow the person concerned to assess the nature and scope as well as possible consequences of the clinical study\n* pregnant or breastfeeding women\n* Signs that the person taking part is unlikely to comply with the therapy (e.g. unwillingness to cooperate)","ALL","18 Years",{"count":85,"type":86},30,"ESTIMATED","INTERVENTIONAL",[89],"PHASE2","The study examines the diagnostic precision of endosonography, mpMRI and PET\u002FCT in defining tumor boundaries and tumor spread before and after neoadjuvant therapy and definitive surgery.",[92,93],"Esophagus Cancer, Stage I","Esophagus Cancer, Stage II","2026-03-06",{"date":96,"type":97},"2026-03-10","ACTUAL",{"date":99,"type":97},"2024-03-01",{"date":101,"type":86},"2028-04",{"name":5,"class":6},1]